Sources Say Amgen Plans To Sell Biotech Japanese Unit (Japan)
This article was originally published in PharmAsia News
The world's largest biotechnology company, Amgen plans cost reductions, beginning by closing its Japan unit, according to sources. U.S.-based Amgen is suffering a decline in sales and is asking $403 million for its Tokyo operation, beginning the talks with Japanese drugmakers. A spokeswoman called the reports "speculation." The Japan unit develops biotech treatments for asthma, cancer and rheumatoid arthritis in Japan. (Click here for more
You may also be interested in...
Eyeing the looming 2011 patent expiration of its top-seller Actos (pioglitazone), Takeda has acquired exclusive Japanese development and commercialization rights, and in one case global rights, to 13 of Amgen's clinical candidates, at a potential cost of up to $1.2 billion
As FDA decision on Alzheimer’s product approaches, new paper outlines Lilly’s arguments for unfettered Medicare coverage for donanemab once it is approved.
Of three accelerated approval drugs that have been ordered withdrawn to date, Pepaxto marks the shortest interval between the FDA drugs center's withdrawal proposal and the agency’s final order, suggesting that FDORA’s expedited withdrawal procedures helped move things along more quickly.